基于治疗前PSMA PET/CT肿瘤与肾脏摄取比值及治疗后肿瘤剂量评估预测mCRPC患者对177Lu-PSMA治疗的反应
本研究纳入30例转移性去势抵抗性前列腺癌患者,每例至少接受3个周期177Lu-PSMA治疗,分析骨与淋巴结转移灶的177Lu-PSMA吸收剂量并与其疗效关联,同时评估治疗前PSMA PET/CT预测反应的能力。结果显示应答者淋巴结和骨病灶吸收剂量显著高于无应答者,最高剂量出现在第一周期,第二周期起下降;治疗前PET/CT的肿瘤与肾脏摄取比值在应答者与无应答者间差异显著。
要点
- 第一周期应答者淋巴结病灶平均剂量3.73±1.65 Gy/GBq,无应答者1.86±1.25 Gy/GBq(P<0.01)。
- 第一周期应答者骨病灶平均剂量3.47±2.00 Gy/GBq,无应答者1.48±0.95 Gy/GBq(P<0.01)。
- 治疗前PSMA PET/CT的肿瘤与肾脏摄取比值在应答者与无应答者间差异显著(P<0.01)。
核心结论
- 应答者的淋巴结和骨病灶吸收剂量显著更高。
- 淋巴结和骨病灶的最高吸收剂量均出现在第一周期,第二周期起下降,尽管治疗活度不变。
- 或可从治疗前PSMA PET/CT的肿瘤与肾脏摄取比值估计治疗反应。
研究设计与样本
- 研究纳入30例转移性去势抵抗性前列腺癌患者,每例至少接受3个周期177Lu-PSMA治疗。
- 以基线至第三周期治疗后6周的PSA变化分类:应答者为PSA下降≥50%,无应答者为PSA不变或升高。
- 于177Lu-PSMA给药后24、48、168小时行定量SPECT/CT,用剂量学软件计算肿瘤病灶吸收剂量。
- 从治疗前PET/CT测定不同SUV下的肿瘤与肾脏摄取比值。
主要发现
- 无论患者是否应答,肾脏每周期平均剂量为0.55±0.20 Gy/GBq。
- 第一周期淋巴结病灶平均剂量:应答者3.73±1.65 Gy/GBq vs 无应答者1.86±1.25 Gy/GBq(P<0.01)。
- 第一周期骨病灶平均剂量:应答者3.47±2.00 Gy/GBq vs 无应答者1.48±0.95 Gy/GBq(P<0.01)。
- 相邻周期比较,淋巴结病灶平均剂量从第一周期到第二周期降低27%,骨病灶降低33%。
- 治疗前PET/CT显示的淋巴结和骨病灶摄取与肾脏摄取比值,在应答者与无应答者间差异显著(P<0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this study was to analyze the absorbed dose of 177Lu-PSMA in osseous versus lymphatic metastases in patients with metastatic castration-resistant prostate cancer across therapy cycles and to relate those data to therapeutic success. In addition, pretherapeutic prostate-specific membrane antigen (PSMA) PET/CT was evaluated for its ability to predict response behavior. Methods: The study comprised 30 patients with metastatic castration-resistant prostate cancer, each receiving at least 3 cycles of 177Lu-PSMA therapy. Prostate-specific antigen (PSA) values between baseline and 6 wk after the third therapy cycle were used to classify the patients as responders (PSA decline ≥ 50%) or nonresponders (unchanged or increasing PSA level). Quantitative SPECT/CT images were acquired 24, 48, and 168 h after application of 177Lu-PSMA. The absorbed dose for tumor lesions was calculated with dosimetry software. From the pretherapeutic PET/CT scan, the tumor-to-kidney uptake ratio was determined for different SUVs. Results: Regardless of patient response, the kidneys received a mean dose of 0.55 ± 0.20 Gy/GBq per cycle. In the first therapy cycle, the lymph node lesions received a mean dose of 3.73 ± 1.65 Gy/GBq in responders and 1.86 ± 1.25 Gy/GBq in nonresponders (P < 0.01). For bone lesions, the respective mean doses were 3.47 ± 2.00 Gy/GBq and 1.48 ± 0.95 Gy/GBq (P < 0.01). When successive therapy cycles were compared, the mean dose was found to have been reduced from the first to the second cycle by 27% for lymph nodes and by 33% for bone lesions. A significant difference (P < 0.01) in the ratio of lymph node and bone lesion uptake to kidney uptake between responders and nonresponders could be deduced from the pretherapeutic PET/CT scan. Conclusion: Significantly higher doses were achieved for lymph node and bone lesions in responders. The highest absorbed dose, for both lymphatic and osseous lesions, was achieved in the first cycle, decreasing in the second therapy cycle thereafter despite unchanged therapy activities. It may be possible to estimate the response to therapy from the ratio of tumor uptake to kidney uptake obtained from the pretherapeutic PSMA PET/CT scans.
引用
- Hohberg M, Reifegerst M, Drzezga A, et al. Prediction of Response to 177Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC. J Nucl Med. 2023. PMID: 37652546. doi:10.2967/jnumed.122.264953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。